Brokerages expect Hologic, Inc. (NASDAQ:HOLX) to announce earnings per share (EPS) of $0.49 for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Hologic’s earnings, with the lowest EPS estimate coming in at $0.47 and the highest estimate coming in at $0.52. Hologic reported earnings per share of $0.52 in the same quarter last year, which suggests a negative year over year growth rate of 5.8%. The business is expected to announce its next earnings report on Wednesday, February 7th.
On average, analysts expect that Hologic will report full-year earnings of $2.12 per share for the current fiscal year, with EPS estimates ranging from $2.08 to $2.15. For the next fiscal year, analysts expect that the firm will post earnings of $2.35 per share, with EPS estimates ranging from $2.27 to $2.40. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Hologic.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million for the quarter, compared to analyst estimates of $792.54 million. During the same quarter in the prior year, the company posted $0.52 EPS. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year.
A number of analysts have recently commented on HOLX shares. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Needham & Company LLC restated a “buy” rating and set a $50.00 price objective on shares of Hologic in a report on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and set a $45.00 price objective (down from $48.00) on shares of Hologic in a report on Monday, October 9th. Jefferies Group restated a “buy” rating and set a $44.00 price objective (down from $49.00) on shares of Hologic in a report on Tuesday, October 10th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 price objective (down from $50.00) on shares of Hologic in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. Hologic has an average rating of “Buy” and an average target price of $47.54.
Hologic (HOLX) traded down $0.87 during mid-day trading on Friday, hitting $40.85. The stock had a trading volume of 4,390,000 shares, compared to its average volume of 3,207,344. The firm has a market cap of $11,261.69, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 1.97 and a beta of 0.95. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic has a 1-year low of $35.76 and a 1-year high of $46.80.
In related news, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elaine Ullian sold 9,282 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,972 shares of company stock valued at $1,385,977. 0.79% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in HOLX. Grove Bank & Trust increased its holdings in Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 1,535 shares in the last quarter. Hall Laurie J Trustee boosted its position in Hologic by 10.2% in the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after buying an additional 225 shares during the last quarter. Commonwealth Bank of Australia boosted its position in Hologic by 31.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new position in Hologic in the 2nd quarter valued at about $191,000. Finally, National Asset Management Inc. purchased a new position in Hologic in the 2nd quarter valued at about $203,000. Hedge funds and other institutional investors own 93.80% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.